211 related articles for article (PubMed ID: 32679404)
1. Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma.
Yang H; Liu Y; Zhang R; Ye Y; Chen Q; Qin Q; Huang L; Li X; Cai R; Tang H; Jiang W
Oral Oncol; 2020 Nov; 110():104897. PubMed ID: 32679404
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.
Xiang ZZ; He T; Zeng YY; Liu F; Shao BF; Yang T; Ma JC; Wang XR; Yu ST; Liu L
Cancer Med; 2023 Jan; 12(2):1102-1113. PubMed ID: 35852473
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
Liang SB; Teng JJ; Hu XF; Yang XL; Luo M; Fang XN; Liu DS; Chen Y; Fu LW
BMC Cancer; 2017 Jul; 17(1):506. PubMed ID: 28754109
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
7. Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival.
Liu LT; Chen QY; Tang LQ; Zhang L; Guo SS; Xie CM; Liu XW; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Radiology; 2017 Jan; 282(1):171-181. PubMed ID: 27479804
[TBL] [Abstract][Full Text] [Related]
8. Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy.
Chang H; Peng L; Tao YL; Chen C; Xiao WW; Hu YH; Gao YH
Cancer Med; 2019 Jun; 8(6):2823-2831. PubMed ID: 31006996
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of prognostic nutritional index in nasopharyngeal carcinoma: A meta-analysis containing 4511 patients.
Tu X; Ren J; Zhao Y
Oral Oncol; 2020 Nov; 110():104991. PubMed ID: 32919361
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.
Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Li Y; Tang QN; Sun XS; Liang YJ; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
J Natl Compr Canc Netw; 2019 Jun; 17(6):703-710. PubMed ID: 31200353
[TBL] [Abstract][Full Text] [Related]
11. The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.
Miao J; Xiao W; Wang L; Han F; Wu H; Deng X; Guo X; Zhao C
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1263-1273. PubMed ID: 28247035
[TBL] [Abstract][Full Text] [Related]
12. The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.
Peng H; Chen L; Zhang Y; Li WF; Mao YP; Liu X; Zhang F; Guo R; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
Sci Rep; 2016 Apr; 6():24835. PubMed ID: 27099096
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma.
Qamar S; King AD; Ai QH; Mo FKF; Chen W; Poon DMC; Tong M; Ma BB; Yeung DK; Wang YX; Yuan J
Eur Radiol; 2020 Nov; 30(11):6339-6347. PubMed ID: 32588210
[TBL] [Abstract][Full Text] [Related]
14. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A large-scale retrospective study.
Zhang LL; Zhou GQ; Li YY; Tang LL; Mao YP; Lin AH; Ma J; Qi ZY; Sun Y
Cancer Med; 2017 Dec; 6(12):2822-2831. PubMed ID: 29034992
[TBL] [Abstract][Full Text] [Related]
15. Association of tumor downstaging after neoadjuvant chemotherapy with survival in patients with locally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wang W; Peng S; Wu H; Luo Y; Yuan F; Lin Z; Cheng G; Chen S
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2913-2922. PubMed ID: 34160678
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
[TBL] [Abstract][Full Text] [Related]
17. Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
Feng M; Wang W; Fan Z; Fu B; Li J; Zhang S; Lang J
Radiat Oncol; 2013 Sep; 8():208. PubMed ID: 24007375
[TBL] [Abstract][Full Text] [Related]
18. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
19. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy in local-regionally advanced nasopharyngeal carcinoma: A National Cancer Database analysis.
Tam M; Lee A; Wu SP; Gerber NK; Li Z; Givi B; Hu K; Schreiber D
Laryngoscope; 2018 Dec; 128(12):2770-2777. PubMed ID: 30133799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
